Form 4: MIMEDX Director James Bierman Receives Annual Restricted Stock Grant

MIMEDX Group, Inc. Director James L. Bierman was granted 28,609 shares of common stock as part of his annual restricted stock compensation.

Summary

• James L. Bierman, a Director of MIMEDX GROUP, INC. (MDXG), acquired 28,609 shares of common stock on June 18, 2025.
• The shares were granted at a price of $6.47 per share.
• This transaction represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3.
• The award vests upon the earlier of 12 months from the grant date or the next annual meeting of shareholders.
• Following this transaction, Mr. Bierman beneficially owns 212,771 shares of MIMEDX common stock directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine insider transaction (grant), which is expected. It shows continued alignment of director interests with the company, but doesn't indicate significant operational or financial news.

Positives

• The grant of restricted stock aligns the director's interests with long-term shareholder value.
• The transaction is a routine annual grant, indicating stable compensation practices for non-employee directors.

Future Outlook

The restricted stock award vests upon the earlier of 12 months or the next annual meeting of shareholders, indicating a future vesting event.

Industry Context

This Form 4 filing is a standard disclosure of insider equity compensation, common across publicly traded companies, and does not provide broader industry context.

Stakeholder Impact

• Shareholders: The grant slightly increases the number of outstanding shares, but it also aligns the director's interests with long-term shareholder value.
• Director (James L. Bierman): Receives additional equity compensation, increasing his stake in the company.

Next Steps

• The restricted stock award will vest upon the earlier of 12 months from the grant date (June 18, 2025) or the next annual meeting of shareholders.

Key Dates

Keywords

MIMEDX GROUP, MDXG, James L. Bierman, Director, Restricted Stock Grant, SEC Form 4, Insider Transaction, Equity Compensation, Beneficial Ownership